REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Cellular Youth Protocol

Anti-Aging & Longevitybeginner
35
Share
Peptides

2

Avg Daily mcg

5,200

Level

beginner

Added

May 16, 2026

Overview

The Cellular Youth Protocol is a beginner-friendly longevity stack that targets aging at its most fundamental level—cellular DNA integrity and tissue repair signaling. By combining Epithalon with GHK-Cu, this protocol addresses two core mechanisms of biological aging: telomere shortening and extracellular matrix degradation. Epithalon (Epitalon), dosed at 5000mcg daily, is a synthetic tetrapeptide based on the natural pineal gland peptide Epithalamin. Its primary mechanism involves activating telomerase, the enzyme responsible for maintaining telomere length on chromosomes. Telomere attrition is one of the hallmarks of aging identified in modern geroscience research. Studies by Professor Vladimir Khavinson demonstrated that Epithalon treatment increased telomerase activity in human somatic cells, effectively slowing the cellular clock. Beyond telomere maintenance, Epithalon supports melatonin production, antioxidant enzyme regulation, and normalized circadian signaling. GHK-Cu (copper peptide) at 200mcg daily is a naturally occurring tripeptide that declines significantly with age. It functions as a powerful tissue remodeling signal, stimulating collagen synthesis, promoting wound healing, reducing inflammation, and activating DNA repair genes. Research has identified over 4,000 genes modulated by GHK-Cu, many involved in antioxidant defense, stem cell activity, and suppression of fibrous tissue formation. Users commonly report improvements in skin elasticity, hair quality, and recovery from minor injuries. The synergy between these two peptides is elegant: Epithalon preserves cellular replicative capacity from within while GHK-Cu optimizes the extracellular environment and repair signaling. Together they address aging from both the genomic and tissue-structure levels. Protocol Notes: Both peptides are administered subcutaneously. Epithalon is typically cycled in 10-20 day courses with breaks between cycles. GHK-Cu can be run continuously. This stack is ideal for individuals over 35 seeking proactive longevity support, improved skin and tissue quality, and foundational anti-aging benefits without complex dosing schedules.

Dosing Protocol

5,000 mcg

per dose

200 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.